Tramadol abuse and dependence among physicians [4]

JAMA

Volumn 292, Issue 15, 2004, Pages 1818-1819

  Skipper, Gregory E ^a   Fletcher, Carol ^b   Rocha Judd, Rosei ^a   Brase, David ^c  

^a Alabama Physician Health Program   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BUTORPHANOL; CANNABIS; CENTRAL STIMULANT AGENT; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; HYDROCODONE; MORPHINE; OXYCODONE; PENTAZOCINE; PETHIDINE; SEDATIVE AGENT; TRAMADOL;

ANALGESIC ACTIVITY; ANALGESIC AGENT ABUSE; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; PHYSICIAN; PRIORITY JOURNAL; OPIATE ADDICTION; STATISTICS; UNITED STATES;

ALABAMA; HUMANS; MICHIGAN; OPIOID-RELATED DISORDERS; PHYSICIANS; TRAMADOL;

EID: 5444276575     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:116-121.
2. Brinker A, Bonnel RA, Beitz J. Abuse, dependence, or withdrawal associated with tramadol. Am J Psychiatry. 2002;159:881.
3. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2003;21:353-421.
4. Knisely JS, Campbell ED, Dawson KS, Schnoll SH. Tramadol post-marketing surveillance in health care professionals. Drug Alcohol Depend. 2002;68:15-22.
5. Food and Drug Administration Center for Drug Evaluation and Research Drug Abuse Advisory Committee. The Scientific Evidence for Initiating a Scheduling Action for Ultram (tramedol hydrochloride). April 28, 1998. Available at: www.fda .gov/ohrms/dockets/ac/98/transcpt/3411t2.rtf. Accessed August 18, 2004.